Human TNFα was purchased from Peprotech (Cat: 300-01A, Rocky Hill, NJ, USA). Dimethyl fumarate (DMF), DMSO, and
z-VAD-fmk were obtained from Sigma-Aldrich (Cat: V900731, D2650, and C2105, St. Louis, MO, USA).
Octyl-α-ketoglutarate (octyl-α-KG) was from Cayman (Cat: 11970, Ann Arbor, MI, USA). Trichostatin A (TSA) and nicotinamide (NAM) were purchased from MCE (Cat: HY-15144 and HY-B0150, Monmouth Juncton, NJ, USA). Smac mimetic and
5-aza-dC were from Selleck (Cat: S7010 and S1200, Houston, TX, USA).
TNF-α (T, 100 ng/ml), Smac mimetic (S, 5 μM), and
z-VAD-fmk (Z, 20 μM) were used as necroptosis inducers (T/S/Z).
Antibodies used were mouse anti-acetylation (Cat: 66289-1-Ig, Proteintech, Rosemont, IL, USA),
mouse anti-β-actin (Cat: A5441, Sigma), rabbit anti-FH (Cat: 11375-1-AP, Proteintech),
rabbit anti-LMP1 (Cat: ab78113, Abcam, Cambridge, MA, USA),
rabbit anti-MLKL (Cat: M6697, Sigma),
rabbit anti-phosphorylated MLKL (Cat: ab187091, Abcam),
rabbit anti-RIP3 (Cat: ab56164, Abcam),
mouse anti-TET1 (Cat: 61444, Active Motif, Carlsbad, CA, USA).
Shi F., Zhou M., Shang L., Du Q., Li Y., Xie L., Liu X., Tang M., Luo X., Fan J., Zhou J., Gao Q., Qiu S., Wu W., Zhang X., Bode A.M, & Cao Y. (2019). EBV(LMP1)-induced metabolic reprogramming inhibits necroptosis through the hypermethylation of the RIP3 promoter. Theranostics, 9(9), 2424-2438.